Aurora Cannabis Inc. (ACB) Stock Score, Valuation & Financial Research
Aurora Cannabis Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for ACB
Aurora Cannabis Inc. currently has a Wall Street Score of 27/100. The stored market price is $3.82. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Aurora Cannabis Inc. does
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing
ACB financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $3.82
- Market capitalization:
- $236.6M
- Revenue:
- $210.1M
- Net income:
- $-80.2M
- Free cash flow:
- $-26.1M
- Cash:
- $85.8M
- Total debt:
- $16.4M
- EPS:
- -1.40
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 16/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-26.1M, showing cash burn in the current stored period.
- The balance sheet shows $85.8M of cash versus $16.4M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.1 points: ACB increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ACB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.